Loading viewer...
investor_presentation
Format: PDF investor_presentation
Organon investor presentation dated April 2022.
Q1 2022 Earnings OrganonDisclaimer statement
Safe Harbor for Forward -Looking Statements
Except for historical information herein, this presentation includes “forward -looking statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectati onsabout Organon’s future
financial performance and prospects. Forward -looking statements may be identified by words such as “expects,” “intends,” “antici pates,” “plans,”
“believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the
company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or ri sksor uncertainties
materialize, actual results may differ materially from those set forth in the forward -looking statements. Risks and uncertaintie s include, but are not limited
to, an inability to execute on our business development strategy or realize the benefits of our planned acquisitions; general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ong oing COVID -19 pandemic
and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally;
global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in
new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future fina ncial results and performance;
the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instabi lity of international economies and
sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effect iveness of the company’s
patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or re gulatory actions. The company
undertakes no obligation to publicly update any forward -looking statement, whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in the forward -looking statements can be found in the company’s filings with the
Securities and Exchange Commission (SEC), including the company's Annual Report on Form 10 -K for the year ended December 31, 202 1 and
subsequent periodic filings, available at the SEC’s Internet site (www.sec.gov).This text should be viewed in conjunction with Organon’s Q1 2022 earnings call
2Disclaimer statement, cont.
Non-GAAP Information
This presentation contains “non -GAAP financial measures,” which are financial measures that either exclude or include amounts th at are not
Preview truncated — download the full document for the complete content.
investor_presentation
25 Pages
investor_presentation
41 Pages
Pieridae Energy
investor_presentation
8x8 Inc